IL320388A - Macrocyclic KRAS inhibitors and methods of use - Google Patents

Macrocyclic KRAS inhibitors and methods of use

Info

Publication number
IL320388A
IL320388A IL320388A IL32038825A IL320388A IL 320388 A IL320388 A IL 320388A IL 320388 A IL320388 A IL 320388A IL 32038825 A IL32038825 A IL 32038825A IL 320388 A IL320388 A IL 320388A
Authority
IL
Israel
Prior art keywords
macrocyclic
methods
kras inhibitors
kras
inhibitors
Prior art date
Application number
IL320388A
Other languages
English (en)
Hebrew (he)
Inventor
Adriano Bauer
Albert Amegadzie
Andrew Smaligo
Benjamin Wigman
Brian Alan Lanman
Christopher Mohr
Fabien Emmetiere
John Charles Stellwagen
Jose M Medina
Liping H Pettus
Michael Masaharu Yamano
Ning Chen
Primali Vasundera Navaratne
Qingyian Liu
Quentin Tercenio
Rene Rahimoff
Ryan Paul Wurz
Shon Booker
Wei Zhao
Xiaofen Li
Yunxiao Li
Zhichen Wu
Aaron C Siegmund
Jeffrey Jackson
Original Assignee
Amgen Inc
Adriano Bauer
Albert Amegadzie
Andrew Smaligo
Benjamin Wigman
Brian Alan Lanman
Christopher Mohr
Fabien Emmetiere
John Charles Stellwagen
Jose M Medina
Liping H Pettus
Michael Masaharu Yamano
Ning Chen
Primali Vasundera Navaratne
Qingyian Liu
Quentin Tercenio
Rene Rahimoff
Ryan Paul Wurz
Shon Booker
Wei Zhao
Xiaofen Li
Yunxiao Li
Zhichen Wu
Aaron C Siegmund
Jeffrey Jackson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Adriano Bauer, Albert Amegadzie, Andrew Smaligo, Benjamin Wigman, Brian Alan Lanman, Christopher Mohr, Fabien Emmetiere, John Charles Stellwagen, Jose M Medina, Liping H Pettus, Michael Masaharu Yamano, Ning Chen, Primali Vasundera Navaratne, Qingyian Liu, Quentin Tercenio, Rene Rahimoff, Ryan Paul Wurz, Shon Booker, Wei Zhao, Xiaofen Li, Yunxiao Li, Zhichen Wu, Aaron C Siegmund, Jeffrey Jackson filed Critical Amgen Inc
Publication of IL320388A publication Critical patent/IL320388A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL320388A 2022-11-14 2023-11-14 Macrocyclic KRAS inhibitors and methods of use IL320388A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263383674P 2022-11-14 2022-11-14
US202363497978P 2023-04-24 2023-04-24
US202363582751P 2023-09-14 2023-09-14
PCT/US2023/079582 WO2024107686A1 (en) 2022-11-14 2023-11-14 Macrocyclic kras inhibitors and methods of use

Publications (1)

Publication Number Publication Date
IL320388A true IL320388A (en) 2025-06-01

Family

ID=91085388

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320388A IL320388A (en) 2022-11-14 2023-11-14 Macrocyclic KRAS inhibitors and methods of use

Country Status (13)

Country Link
US (3) US20240294551A1 (enExample)
EP (1) EP4598921A1 (enExample)
JP (3) JP7743484B2 (enExample)
KR (1) KR20250095749A (enExample)
CN (1) CN120500482A (enExample)
AU (1) AU2023382606A1 (enExample)
CL (1) CL2025001425A1 (enExample)
CO (1) CO2025006813A2 (enExample)
IL (1) IL320388A (enExample)
MX (1) MX2025005539A (enExample)
PE (1) PE20252237A1 (enExample)
TW (1) TW202430532A (enExample)
WO (1) WO2024107686A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4469164A1 (en) 2023-02-14 2024-12-04 F. Hoffmann-La Roche AG Tricyclic compounds for the treatment of cancer
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025123007A1 (en) * 2023-12-08 2025-06-12 Kestrel Therapeutics Inc. Ras inhibitors and methods of use thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025194057A1 (en) * 2024-03-14 2025-09-18 Amgen Inc. Macrocyclic compounds as modulators of kras and uses thereof
WO2025194054A1 (en) * 2024-03-14 2025-09-18 Amgen Inc. Spirocyclic compounds as modulators of kras and uses thereof
WO2025230862A1 (en) * 2024-04-29 2025-11-06 Amgen Inc. Macrocyclic amino compounds as modulators of kras and uses therof
WO2025230860A1 (en) * 2024-04-29 2025-11-06 Amgen Inc. Solid forms of macrocyclic compounds and uses thereof
WO2025230878A1 (en) * 2024-04-29 2025-11-06 Amgen Inc. Macrocyclic compounds as modulators of kras and uses thereof
WO2025240582A1 (en) * 2024-05-14 2025-11-20 Amgen Inc. Macrocyclic compounds as modulators of kras and uses thereof
WO2025240465A1 (en) * 2024-05-14 2025-11-20 Amgen Inc. Processes for preparing macrocyclic compounds
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041671A1 (en) * 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
CN115003668A (zh) * 2020-01-21 2022-09-02 南京明德新药研发有限公司 作为kras抑制剂的大环类化合物
EP4262807A4 (en) * 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
US11999753B2 (en) * 2020-12-16 2024-06-04 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-KRas inhibitors
MX2023008463A (es) * 2021-02-16 2023-12-07 Leidos Biomedical Res Inc Composiciones y métodos para la inhibición del gen del virus de sarcoma de rata kirsten (kras).
US20240174691A1 (en) * 2021-03-17 2024-05-30 Genfleet Therapeutics (Shanghai) Inc. Pyrimidine-fused cyclic compound, preparation method therefor and use thereof
WO2022214102A1 (zh) * 2021-04-09 2022-10-13 杭州英创医药科技有限公司 作为kras g12d抑制剂的杂环化合物
CN115304623A (zh) * 2021-04-30 2022-11-08 四川海思科制药有限公司 一种嘧啶并环衍生物及其在医药上的应用

Also Published As

Publication number Publication date
JP2024071370A (ja) 2024-05-24
WO2024107686A1 (en) 2024-05-23
TW202430532A (zh) 2024-08-01
CL2025001425A1 (es) 2025-08-29
KR20250095749A (ko) 2025-06-26
AU2023382606A1 (en) 2025-05-08
US20250304599A1 (en) 2025-10-02
JP7743484B2 (ja) 2025-09-24
JP2025539080A (ja) 2025-12-03
US20240294551A1 (en) 2024-09-05
JP2025179208A (ja) 2025-12-09
US20250236631A1 (en) 2025-07-24
CN120500482A (zh) 2025-08-15
PE20252237A1 (es) 2025-09-15
MX2025005539A (es) 2025-06-02
EP4598921A1 (en) 2025-08-13
CO2025006813A2 (es) 2025-06-06

Similar Documents

Publication Publication Date Title
IL320388A (en) Macrocyclic KRAS inhibitors and methods of use
EP4143196A4 (en) PI3K-A INHIBITORS AND METHODS OF USE THEREOF
IL312348A (en) HIF-2ALPHA inhibitors and methods of using it
IL318169A (en) Apol1 inhibitors and methods of use are the same
IL318748A (en) Compositions and methods for inhibiting KRAS
IL319748A (en) PCSK9 inhibitors and methods of using them
IL314320A (en) Compounds and methods of use
EP4370124A4 (en) PI3KA INHIBITORS AND METHODS OF USE THEREOF
IL316619A (en) PI3Kα inhibitors and methods of using them
IL310812A (en) SOLID FORMS OF SPIROTRICYCLIC APOL1 INHIBITORS AND METHODS OF USING THEM
IL321357A (en) KIF18A inhibitors and their uses
IL299700A (en) KCNT1 inhibitors and methods of use
IL318393A (en) Azaquinazoline compounds and methods of use
IL314277A (en) Anti-B7-H3 compounds and methods of use
ES3049868T3 (en) Farnesyl-transferase inhibitors and kras inhibitors for treating kras mutant cancers
IL314594A (en) Heterocyclic compounds and methods of use
EP4329735A4 (en) KCNT1 INHIBITORS AND METHODS OF USE
IL299163A (en) Macrocyclic compounds and methods of using them
CA3272712A1 (en) Macrocyclic kras inhibitors and methods of use
IL324181A (en) MRGPRX2 inhibitors and methods of using them
HK40108895A (zh) Kras g12d抑制剂与pi3ka抑制剂的组合及相关治疗方法
HK40108579A (zh) Kras g12d抑制剂与伊立替康的组合及相关治疗方法
GB202315697D0 (en) Compounds and methods of use
IL314338A (en) Anti-B7-H3 compounds and methods of use
GB202212937D0 (en) Compounds and methods of use